GuidelinesOther guideline
Systemic Hormonal Preparations, excl. Sex Hormones and Insulins
Adrenocorticotrophic hormone (ACTH) Somatropin (Growth Hormone) Ornipressin Octreotide (Short-acting) Octreotide, Lanreotide ATC Code H01AA01 Medicine Adrenocorticotrophic hormone (ACTH) Indication Infantile spasms NEMLC Recommendation Not Approved Review Indicators Well controlled studies of proven efficacy of ACTH Date Ratified September 2010 ATC Code H01AC01 Medicine Somat
Adrenocorticotrophic hormone (ACTH)
| ATC Code | H01AA01 |
| Medicine | Adrenocorticotrophic hormone (ACTH) |
| Indication | Infantile spasms |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Well controlled studies of proven efficacy of ACTH |
| Date Ratified | September 2010 |
| ATC Code | H01AC01 |
| Medicine | Somatropin (Growth Hormone) |
| Indication | Turner’s syndrome |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Improved cost- effectiveness |
| Date Ratified | 20 September 2007 |
| ATC Code | H01AC01 |
| Medicine | Somatropin (Growth Hormone) |
| Indication | Prader Willi syndrome |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Price |
| Date Ratified | 20 September 2007 |
| ATC Code | H01AC01 |
| Medicine | Somatropin (Growth Hormone) |
| Indication | Intrauterine growth failure |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Price |
| Date Ratified | 20 September 2007 |
| ATC Code | H01AC01 |
| Medicine | Somatropin (Growth Hormone) |
| Indication | Idiopathic short stature |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Improved cost-effectiveness |
| Date Ratified | 20 September 2007 |
| ATC Code | H01AC01 |
| Medicine | Somatropin (Growth Hormone) |
| Indication | Chronic renal insufficiency |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Evidence of benefit |
| Date Ratified | 20 September 2007 |
| ATC Code | H01AC01 |
| Medicine | Somatropin (Growth Hormone) |
| Indication | Growth hormone deficiency |
| NEMLC Recommendation | Approved Approved for confirmed growth hormone deficiency for use by endocrinologists only Rationale: - The condition is a well-defined deficiency state that can be managed and monitored - Number of patients requiring treatment is small |
| Review Indicators | New evidence on quality of life assessment in local and specific populations |
| Date Ratified | 24 July 2008 |
| ATC Code | H01BA05 |
| Medicine | Ornipressin |
| Indication | Bleeding associated with bronchoscopy and renal biopsy |
| NEMLC Recommendation | Not Approved |
| Review Indicators | New high quality evidence of superior efficacy to adrenalin |
| Date Ratified | 29 October 2012 |
| ATC Code | H01CB02 |
| Medicine | Octreotide (Short-acting) |
| Indication | Persistent neonatal hyperinsulinism and hypoglycaemia |
| NEMLC Recommendation | Approved The condition is rare; usage is for short term; alternative agents are limited and the consequences of not having treatment available are serious |
| ATC Code | H01CB |
| Medicine | Somatostatin analogs: Octreotide, Lanreotide |
| Indication | Neuro-endocrine tumours |
| NEMLC Recommendation | Not Approved |
| Review Indicators | Long term survival and quality of life data |
| Date Ratified | 26 March 2015 |